UA73302C2 - Oral dosage form of omeprazole without enteric coating - Google Patents

Oral dosage form of omeprazole without enteric coating Download PDF

Info

Publication number
UA73302C2
UA73302C2 UA2001128420A UA2001128420A UA73302C2 UA 73302 C2 UA73302 C2 UA 73302C2 UA 2001128420 A UA2001128420 A UA 2001128420A UA 2001128420 A UA2001128420 A UA 2001128420A UA 73302 C2 UA73302 C2 UA 73302C2
Authority
UA
Ukraine
Prior art keywords
dosage form
core material
form according
omeprazole
weight
Prior art date
Application number
UA2001128420A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UA73302C2 publication Critical patent/UA73302C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UA2001128420A 1999-06-22 2000-06-20 Oral dosage form of omeprazole without enteric coating UA73302C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902386A SE9902386D0 (sv) 1999-06-22 1999-06-22 New formulation
PCT/SE2000/001310 WO2000078293A1 (en) 1999-06-22 2000-06-20 New formulation

Publications (1)

Publication Number Publication Date
UA73302C2 true UA73302C2 (en) 2005-07-15

Family

ID=20416209

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001128420A UA73302C2 (en) 1999-06-22 2000-06-20 Oral dosage form of omeprazole without enteric coating

Country Status (29)

Country Link
EP (1) EP1191926B1 (enExample)
JP (1) JP2003502359A (enExample)
KR (1) KR100717661B1 (enExample)
CN (1) CN1243547C (enExample)
AT (1) ATE291901T1 (enExample)
AU (1) AU778158B2 (enExample)
BR (1) BR0011894A (enExample)
CA (1) CA2376226C (enExample)
CZ (1) CZ20014579A3 (enExample)
DE (1) DE60019116T2 (enExample)
DK (1) DK1191926T3 (enExample)
EE (1) EE200100693A (enExample)
ES (1) ES2235912T3 (enExample)
HK (1) HK1044480B (enExample)
HU (1) HUP0201489A3 (enExample)
IL (2) IL146818A0 (enExample)
IS (1) IS6209A (enExample)
MX (1) MXPA01012636A (enExample)
NO (1) NO20016346L (enExample)
NZ (1) NZ516186A (enExample)
PL (1) PL352873A1 (enExample)
PT (1) PT1191926E (enExample)
RU (1) RU2240110C2 (enExample)
SE (1) SE9902386D0 (enExample)
SK (1) SK285326B6 (enExample)
TR (1) TR200103693T2 (enExample)
UA (1) UA73302C2 (enExample)
WO (1) WO2000078293A1 (enExample)
ZA (1) ZA200109803B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
EP1605919A1 (en) * 2003-02-28 2005-12-21 Ranbaxy Laboratories, Ltd. Stable pharmaceutical composition of rabeprazole and processes for their preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005027876A1 (en) * 2003-08-28 2005-03-31 Ranbaxy Laboratories Limited Pharmaceutical compositions of benzimidazole and processes for their preparation
EP1660052A2 (en) * 2003-09-03 2006-05-31 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20080214618A1 (en) * 2004-08-23 2008-09-04 Auckland Uniservices Limited Gastric Therapies Amd Compositions Therefor
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
CA2578626C (en) 2005-06-27 2011-07-19 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
MY151468A (en) * 2005-12-28 2014-05-30 Takeda Pharmaceutical Controlled release solid preparation
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
AU2007278986B2 (en) 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
WO2008044236A2 (en) * 2006-10-10 2008-04-17 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
JP2012531409A (ja) 2009-06-25 2012-12-10 アストラゼネカ・アクチエボラーグ Ｎｓａｉｄ関連潰瘍を発症するリスクがある患者の処置方法
CA2835845C (en) * 2011-05-13 2020-07-28 Emotional Brain B.V. Drug delivery system
EP2586429A1 (en) * 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Multi-unit drug delivery device for pulsatile or sustained release
EP2797600A4 (en) 2011-12-28 2015-09-16 Pozen Inc IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
WO2013122554A1 (en) 2012-02-14 2013-08-22 Mahmut Bilgic Pellet formulations comprising esomeprazole
CN103127026B (zh) * 2013-02-05 2017-02-15 悦康药业集团有限公司 一种奥美拉唑肠溶胶囊及其制备方法
AU2014374361B9 (en) 2013-12-31 2019-07-04 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
RU2614730C1 (ru) * 2016-02-05 2017-03-28 Игорь Юрьевич Чичерин Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза
WO2017145146A1 (en) * 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
JP6426115B2 (ja) * 2016-04-06 2018-11-21 ニプロ株式会社 カルシウムブロッカーを含有する固形医薬組成物
JP6462625B2 (ja) * 2016-04-06 2019-01-30 ニプロ株式会社 カルシウムブロッカーを含有する錠剤
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN109125282B (zh) * 2018-09-05 2020-07-14 珠海润都制药股份有限公司 一种奥美拉唑肠溶胶囊及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
ZA979937B (en) * 1996-11-06 1999-05-18 Sharmatek Inc Delayed delivery system for acid-sensitive drugs
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6328993B1 (en) * 1997-12-08 2001-12-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for an acid liable active proton pump inhibitor
CA2340054C (en) * 1998-08-12 2005-10-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles

Also Published As

Publication number Publication date
EP1191926A1 (en) 2002-04-03
WO2000078293A1 (en) 2000-12-28
AU778158B2 (en) 2004-11-18
NZ516186A (en) 2003-11-28
AU6034400A (en) 2001-01-09
CZ20014579A3 (cs) 2002-05-15
NO20016346D0 (no) 2001-12-21
KR100717661B1 (ko) 2007-05-14
MXPA01012636A (es) 2002-06-21
ATE291901T1 (de) 2005-04-15
CA2376226C (en) 2009-10-20
CN1356893A (zh) 2002-07-03
HK1044480B (en) 2005-08-26
IL146818A (en) 2007-10-31
HUP0201489A3 (en) 2004-05-28
DK1191926T3 (da) 2005-06-13
RU2240110C2 (ru) 2004-11-20
ES2235912T3 (es) 2005-07-16
SK18252001A3 (sk) 2002-09-10
SE9902386D0 (sv) 1999-06-22
PT1191926E (pt) 2005-07-29
EP1191926B1 (en) 2005-03-30
DE60019116D1 (de) 2005-05-04
CA2376226A1 (en) 2000-12-28
TR200103693T2 (tr) 2002-05-21
PL352873A1 (en) 2003-09-08
EE200100693A (et) 2003-02-17
BR0011894A (pt) 2002-04-02
SK285326B6 (sk) 2006-11-03
CN1243547C (zh) 2006-03-01
NO20016346L (no) 2002-02-18
KR20020012002A (ko) 2002-02-09
HUP0201489A2 (hu) 2002-11-28
HK1044480A1 (en) 2002-10-25
DE60019116T2 (de) 2006-02-09
IL146818A0 (en) 2002-07-25
IS6209A (is) 2001-12-21
ZA200109803B (en) 2003-02-28
JP2003502359A (ja) 2003-01-21

Similar Documents

Publication Publication Date Title
UA73302C2 (en) Oral dosage form of omeprazole without enteric coating
RU2207121C2 (ru) Фармацевтический препарат омепразола
RU2179453C2 (ru) Пероральные фармацевтические лекарственные формы, включающие ингибитор протонного насоса и антацидное вещество или альгинат
JP4907765B2 (ja) 経口医薬パルス放出剤形
AU774278B2 (en) Pharmaceutical formulation comprising omeprazole
AU2005319732B2 (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
JP3725542B2 (ja) ピコサルフェート剤形
JPH09502739A (ja) 複数単位の錠剤化された剤形▲ｉ▼
JP2000514051A (ja) ベンズイミダゾール誘導体を活性成分とする経口投与用の安定な薬剤形およびその製造方法
AU2006321007A1 (en) Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid
KR20070083956A (ko) 양성자 펌프 억제제를 위한 신규 변형 방출 정제 제형
EA003512B1 (ru) Желудочная и/или дуоденальная клейкая лекарственная форма
CZ194698A3 (cs) Orální farmaceutický přípravek obsahující 5-ASA s modifikovaným uvolňováním
JPWO2007074910A1 (ja) 放出制御固形製剤
JP5452056B2 (ja) 経口薬
BRPI0619391A2 (pt) forma de dosagem farmacêutica oral, processo para a manufatura de uma forma de dosagem de combinação fixa oral, uso de uma forma de dosagem, e, forma de combinação fixa oral farmacêutica
TR201606245A2 (tr) Oral antasi̇d formülasyonlar